Search

Your search keyword '"De Bona, M"' showing total 9 results
Start Over Author "De Bona, M" Language italian
9 results on '"De Bona, M"'

1. Qualità della vita e trapianto di fegato

Author

RUPOLO GP, PONTON P, FELTRIN A, SCOCCO P, RAMPAZZO M, DE BONA M, FAGIUOLI S, JEMMOLO R, DE LEO D, BURRA P, Rupolo, G, Ponton, P, Feltrin, A, Scocco, P, Rampazzo, M, DE BONA, M, Fagiuoli, S, Jemmolo, R, DE LEO, D, and Burra, P

Subjects
Qualità della vita trapianto di fegato
Published
2001

2. Neoplasie de novo dopo trapianto di fegato

Author

Buda, A, Burra, P, De Bona, M, Fagiuoli, S, Cillo, U, Farinati, F, Fagiuoli, S, Chiaramonte, M, Buda, A, Burra, P, De Bona, M, Cillo, U, and Farinati, F

Subjects
Neoplasie de novo, trapianto di fegato
Published
2001

3. Qualità di vita (QoL) dopo trapianto di fegato

Author

De Bona M, Burra P, Casagrande F, Buda A, Ponton P, Feltrin A, Ermani M, Jemmlo RM, Fagiuoli S, Boccagli P, Gerunda G, Ruolo GP, Naccarato R., De Bona, M, Burra, P, Casagrande, F, Buda, A, Ponton, P, Feltrin, A, Ermani, M, Jemmlo, R, Fagiuoli, S, Boccagli, P, Gerunda, G, Ruolo, G, and Naccarato, R

Subjects
Qualità di vita, trapianto di fegato
Published
1999

5. Complicanze gastrointestinali dopo trapianto di fegato

Author

De Bona M, Buda A, Targhetta S, Russo FP, Burra P, Boccagli P, Cillo U, Zanus G, D’amico D, Naccarato R, Fagiuoli S, De Bona, M, Buda, A, Targhetta, S, Russo, F, Burra, P, Boccagli, P, Cillo, U, Zanus, G, D’Amico, D, Naccarato, R, and Fagiuoli, S

Subjects
Complicanze gastrointestinali, trapianto di fegato
Published
1999

6. Qualità di vita del paziente con cirrosi: effetto del trapianto di fegato

Author

Burra P, De Bona M, Jemmolo RM, Boccagli P, Tedeschi U, Gerunda G, Fagiuoli S, Ruolo GP, Naccarato R, Burra, P, De Bona, M, Jemmolo, R, Boccagli, P, Tedeschi, U, Gerunda, G, Fagiuoli, S, Ruolo, G, and Naccarato, R

Subjects
Qualità di vita, cirrosi, trapianto di fegato
Published
1997

7. ricorrenza di infezione da HCV e qualità di vita dopo trapianto di fegat

Author

De Bona M, Burra P, Ponton P, Jemmolo RM, Destro C, Boccagni P, Buda A, Targhetta S, Fagiuoli S, Rupolo GP, Naccarato R, De Bona, M, Burra, P, Ponton, P, Jemmolo, R, Destro, C, Boccagni, P, Buda, A, Targhetta, S, Fagiuoli, S, Rupolo, G, and Naccarato, R

Subjects
infezione da HCV qualità di vita trapianto di fegato
Published
1997

8. Neoplasie de novo dopo trapianto di fegato

Author

Buda A, Burra P, De Bona M, Fagiuoli S, Cillo U, Zanus G, Graziotto A, Naccarato R, Buda, A, Burra, P, De Bona, M, Fagiuoli, S, Cillo, U, Zanus, G, Graziotto, A, and Naccarato, R

Subjects
trapianto di fegato, Neoplasie de novo
Published
1997

9. [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].

Author

Di Mario F, Grasso GA, Battaglia G, De Boni M, Vianello F, De Bona M, Pasquino M, Chiozzini G, and Saggioro A

Subjects
Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Omeprazole therapeutic use, Ranitidine therapeutic use, Recurrence, Time Factors, Duodenal Ulcer economics, Duodenal Ulcer prevention & control, Omeprazole administration & dosage, Omeprazole economics, Ranitidine administration & dosage, Ranitidine economics
Abstract

Prevention of ulcer relapse and of its complications is a problem which remains to be solved. Our study involved 250 patients, with healed duodenal ulcer. We evaluated efficacy and costs of three different maintenance therapies: ranitidine 150 mg/day, omeprazole 20 mg/day every other day and omeprazole 20 mg/day. Six months later, we found the incidence of relapse to be 24.4% (32/131) in the once-a-day ranitidine group, 19.7% (13/66) in the day every-other-day omeprazole group, and 3.8% (2/53) in the once-a-day omeprazole group. Further, we evaluated costs relative to relapsing patients, and total costs for each treatment group. From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results